Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ceftobiprole

            Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Shenzhen China Resources Gosun Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 06, 2020

            Details:

            With the Drug Approval License Authorization, Zevtera is now approved in China for the treatment of adult patients with community-acquired pneumonia (CAP) and adult patients with hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Isavuconazonium Sulfate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 07, 2020

            Details:

            Center for Drug Evaluation at the National Medical Products Administration of China has accepted Basilea's marketing authorization application for isavuconazole (Cresemba®) to treat patients with mucormycosis, which was submitted by Basilea’s license partner Pfizer Inc.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Isavuconazonium Sulfate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: $0.5 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement July 15, 2020

            Details:

            Basilea Pharmaceutica reported that its license partner, Pfizer has launched the antifungal Cresemba® (isavuconazole) in Taiwan.